Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Kamal Menghrajani

Leukemia · MGH

View

Dr. Naval Daver

Leukemia · MD Anderson Cancer Center

View

Dr. Daniel Pollyea

Leukemia · CU Anschutz Medical Campus

View

Dr. Jessica Altman

Leukemia · Northwestern Medicine

View

Dr. Shella Saint Fleur-Lominy

Leukemia · UMSOM

View

Dr. Azra Raza

Leukemia · CUIMC

View

Dr. Molly Imgruet

Leukemia · Stanford

View

Dr. Talal Hilal

Lymphoma · Mayo Clinic College of Medicine

View

Dr. Midhun Malla

GI Oncology · UAB

View

Dr. Saad Usmani

Myeloma · MSK

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms
    RMDr. Razan Mohty

    Dr. Razan Mohty

    Hematology & Oncology · Leukemia
    University of Alabama at Birmingham
    razan

    Research

    Blinatumomab nonresponse correlates with poor survival after brexucabtagene autoleucel in B-cell ALL

    2026

    Via Blood

    Research

    Predictors of complete molecular response and impact of allogeneic hematopoietic stem cell transplantation in Ph+ ALL (COMMAND)

    2026

    Via Leukemia & Lymphoma

    Research

    Gilteritinib for Prevention of Post-transplant Relapse in Patients With Acute Myeloid Leukemia and FLT3-ITD Mutation

    2026

    Via Transplantation and Cellular Therapy

    Research

    Efficacy of bispecific T-cell engagers after CAR T-cell therapy failure in aggressive large B-cell lymphoma

    2026

    Via Current Research in Translational Medicine

    Research

    Higher Cumulative Cytarabine Consolidation Improves Survival in Older Adults with Acute Myeloid Leukemia

    2026

    Via Cancers

    Research

    A novel severe toxicity-free, and progression-free survival endpoint predicts outcomes after CD19 chimeric antigen receptor-T cell therapy in large B-cell lymphoma

    2026

    Via Bone Marrow Transplantation

    Research

    sMAdCAM-1 is decreased after allo-HCT, along with gut microbiota dysbiosis, and is associated with hematopoietic recovery

    2025

    Via HemaSphere

    Research

    Chimeric antigen receptor T cell therapy in octogenarians with B cell lymphoma: a real-world US multicenter study

    2025

    Via Bone Marrow Transplantation

    Research

    Outcomes With Venetoclax 50 mg, Hypomethylating Agents, and Voriconazole or Posaconazole in AML

    2025

    Via EJHaem

    Research

    Malignancies after Chimeric Antigen Receptor T Cell Therapy

    2025

    Via Transplantation and Cellular Therapy

    Research

    Real-World Evidence of Treatment-Free Remission Strategies and Outcomes in Chronic Myeloid Leukemia

    2025

    Via Cancers

    Research

    Outcomes with intensive chemotherapy, compared to hypomethylating agent + venetoclax, in patients with AML

    2025

    Via Leukemia Research

    Research

    CD19 Directed CAR T Therapy for Transformed Follicular Lymphoma: A CIBMTR Analysis

    2025

    Via American Journal of Hematology

    Research

    Treatment of Diffuse Large B-cell Lymphoma Progressing or Relapsing after Chimeric Antigen Receptor T-cell Therapy

    2025

    Via Transplantation and Cellular Therapy

    Research

    Efficacy of eltrombopag for treatment of thrombocytopenia in the setting of allogeneic hematopoietic cell transplantation

    2025

    Via Bone Marrow Transplantation